

Press release

31.05.24

Vincent Gruntz is to be the new CEO of SAKK

The Board of the Swiss Group for Clinical Cancer Research (SAKK) has elected Vincent Gruntz as its new CEO. The 43-year-old economist, who has a wealth of experience in healthcare and the pharmaceutical industry, will succeed Dr. Hans Rudolf Keller, who is leaving SAKK.

After two and a half years as CEO, Dr. Hans Rudolf Keller has decided to leave SAKK. He has successfully defined SAKK's targets for the coming years as well as its strategy, while also developing efficient structures and processes and ensuring responsible corporate governance. In collaboration with the Board and his team at the Competence Center, he has fine-tuned SAKK's strategy and optimized numerous processes, thus laying the groundwork for the organization's development going forward. The Board would like to thank him for his hard work and dedication.

The SAKK Board has now selected Dr. Hans Rudolf Keller's successor, electing Vincent Gruntz as the new CEO. An economics graduate (lic. rer. pol.), he has held various management positions within the pharma industry and also worked as an economist in the Health and Accident Insurance Directorate at the Federal Office of Public Health for a number of years. More recently, he was responsible for the entire cell therapies portfolio as Vice President and International Head of Cell and Gene Therapies at Novartis. He will take up his position at SAKK in September 2024.

A 43-year-old Swiss citizen, Vincent Gruntz is married with two sons and lives with his family in Liebefeld near Bern. Well-networked in the Swiss healthcare field, he also possesses in-depth knowledge of research and drug development acquired during his various management roles in the pharma industry. His outstanding track record and his eagerness to guarantee a strong future for SAKK were the factors that convinced the Board to appoint him as CEO. When asked about his new role, Gruntz said: "I first learned of SAKK and its valuable work during my time as General Manager at Novartis Oncology in Switzerland. In my view, SAKK is uniquely positioned to establish Switzerland as a world leader in terms of clinical cancer research as well as in areas such as data quality, digitalization and innovation in the field of cancer research. I can't wait to join the team and help to write the next chapter of SAKK's success story." The Board is very much looking forward to working with Vincent Gruntz.

For questions and further information

Prof. Dr. med. Miklos Pless, President, +41 79 699 30 89, miklos.pless@sakk.ch

You can find **further information** about SAKK at: www.sakk.ch



About the Swiss Group for Clinical Cancer Research (SAKK)

SAKK is the biggest competence center for clinical cancer research in Switzerland. The not-for-profit organization was established as an association in 1965. As a competence center, the objective of SAKK is to network its members, research cancer therapies, refine existing treatments and improve the chances of a cure for cancer patients. This is achieved through cooperation within Switzerland and with partners in other countries. Researching physicians are helped to develop and conduct multicenter and interdisciplinary trials independently of the pharmaceutical industry. The members of SAKK are the clinical oncology centers at university, cantonal and private hospitals. They work with other hospitals and physicians, and together form the SAKK network.